MedTrace Logo

Safety, Tolerability and Clinical Activity of ASM-024 in Subjects With Mild Allergic Asthma

NCT01092403 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2012-01-26

No results posted yet for this study

Summary

The study will assess the safety, tolerability and clinical activity of ASM-024 in subjects with mild allergic asthma.

Conditions

  • Mild Allergic Asthma

Interventions

DRUG

ASM-024

ASM-024 50 mg of ASM-024 or 200 mg once daily by inhalation

DRUG

Placebo

Placebo once daily by inhalation

Sponsors & Collaborators

  • Asmacure Ltée

    lead INDUSTRY

Principal Investigators

  • Louis-Philippe Boulet, MD · Institut universitaire de cardiologie et de pneumologie de Québec, University Laval

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2011-12-31
Completion
2012-01-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01092403 on ClinicalTrials.gov